LTP

Every compound in the sci-wiki that affects ltp; the ones you can source are floated to the front, then the reference-only entries. Tap any for the full entry, mechanism, and outlets.

0 sourced · 4 reference

←ltp4/4

Neuroprotection

BAY 60-7550

BAY 60-7550 is a potent, selective phosphodiesterase-2 (PDE2) inhibitor. By blocking PDE2 it raises both neuronal cAMP and cGMP, driving CREB phosphorylation and BDNF expression while enhancing hippocampal long-term potentiation and memory consolidation. It sits squarely in the cAMP→CREB→BDNF neighborhood but, importantly, acts on PDE2 rather than PDE4, giving it a dual second-messenger action distinct from the more familiar PDE inhibitors.

reference

Nootropic

CX-516

CX-516 (Ampalex) is the first-in-class ampakine, developed by Cortex Pharmaceuticals, historically important as the compound that established AMPA-receptor positive modulation as a cognition strategy. It facilitates long-term potentiation and memory in animal models, but its weak potency and short half-life undermined every human trial.

reference

Nootropic

Rolipram

Rolipram (ZK 62711) is the prototypical PDE4 inhibitor and the reference compound for the entire class. Developed by Schering as an antidepressant in the 1980s, it was abandoned over severe emesis but went on to become the single most-studied molecule in the cAMP/CREB-enhances-memory literature. It reliably converts early- to late-long-term potentiation and rescues memory across Alzheimer, aging and Rubinstein-Taybi models, making it the yardstick every newer PDE4 memory drug is measured against.

reference

Nootropic

Tulrampator

Tulrampator (S-47445) is a selective positive allosteric modulator of AMPA-type glutamate receptors developed by Servier. Beyond acutely potentiating glutamatergic transmission, it upregulates BDNF and NT-3, activates the mTOR/CREB plasticity pathway, and rescues age-related deficits in hippocampal long-term potentiation and synaptic architecture in animals. It is the best-characterized modern AMPA-PAM and the only ampakine of its cohort to reach large Phase 2 human trials.

reference